Levotuss

Levodropropizine, the active ingredient in Levotuss, is an antitussive presented as an oral formulation for oral use. It acts on the peripheral cough reflex to reduce the frequency and intensity of dry, non‑productive coughs in both adult and pediatric patients when prescribed.

GNH USA supplies Levotuss as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing products sourced from the European Union market under strict quality standards. The company ensures regulatory compliance, reliable logistics and responsive technical support for global customers.

Levodropropizine is used as an antitussive to manage coughs arising from irritation of the respiratory tract. - Cough: Reduces frequency and severity of acute cough episodes. - Dry cough: Suppresses non‑productive cough without causing sedation. - Irritative cough: Alleviates cough caused by throat irritation or mild upper respiratory infections.

Levodropropizine may be associated with several adverse reactions, which are generally mild but can be serious in rare cases.

Common Side Effects: - Nausea: mild stomach upset that may be transient and resolve without intervention. - Dizziness: transient light‑headedness, often occurring shortly after dosing and usually subsiding quickly. - Headache: occasional mild headache that does not typically require specific treatment.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, swelling of the face, lips or tongue indicating hypersensitivity. - Hepatic dysfunction: elevated liver enzymes or jaundice, requiring laboratory monitoring in susceptible individuals. - Anaphylaxis: acute, potentially life‑threatening allergic response with respiratory distress and cardiovascular collapse.

When prescribing Levodropropizine, several precautionary measures should be observed to ensure safe use. - Age limitation: use with caution in children under two years of age. - Hepatic impairment: adjust use in patients with liver disease and monitor liver function. - Renal impairment: consider dose adjustment in severe renal dysfunction. - Concomitant CNS depressants: avoid combining with strong sedatives as additive effects may occur. - Pregnancy and lactation: assess risk‑benefit before use; limited data available. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and direct sunlight.

Levodropropizine can interact with other medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - MAO inhibitors: risk of enhanced serotonergic effects; avoid concurrent use. - Strong CYP3A4 inhibitors: may increase plasma levels leading to toxicity.

Moderate Interactions (Monitor Closely): - CNS depressants: additive sedation or dizziness; monitor patient response. - Antihistamines: potential increase in antitussive effect; adjust dose if needed. - Antacids: may alter absorption; separate administration times.